Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation supression therapy
US10172836B2 · kind B2 · utility
2Cited by
13References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2018 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Jan 19, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.